Compare IPHA & MRCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | IPHA | MRCC |
|---|---|---|
| Founded | 1999 | 2011 |
| Country | France | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 174.2M | 151.2M |
| IPO Year | 2019 | 2012 |
| Metric | IPHA | MRCC |
|---|---|---|
| Price | $1.85 | $6.71 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 3 | 1 |
| Target Price | $5.00 | ★ $8.00 |
| AVG Volume (30 Days) | 21.7K | ★ 102.5K |
| Earning Date | 09-17-2025 | 11-05-2025 |
| Dividend Yield | N/A | ★ 15.02% |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $14,839,695.00 | ★ $43,742,000.00 |
| Revenue This Year | $22.29 | N/A |
| Revenue Next Year | $43.90 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.47 | $5.86 |
| 52 Week High | $3.51 | $8.85 |
| Indicator | IPHA | MRCC |
|---|---|---|
| Relative Strength Index (RSI) | 42.81 | 55.06 |
| Support Level | $1.85 | $6.65 |
| Resistance Level | $1.91 | $6.80 |
| Average True Range (ATR) | 0.07 | 0.14 |
| MACD | -0.00 | 0.06 |
| Stochastic Oscillator | 11.63 | 81.30 |
Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. Its approach is to harness the innate immune system through therapeutic antibodies and its ANKET (Antibody-based NK cell Engager Therapeutics) proprietary platform. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, IPH5301, IPH6101, IPH62, IPH6401 and IPH6501.
Monroe Capital Corp is a speciality finance company focused on providing financing to lower middle-market companies, in the U.S. and Canada. The company provides customized financing solutions focused on senior, unitranche, and junior secured debt and unsecured subordinated debt and equity, including equity co-investments in preferred and common stock and warrants.